Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.
Stocks · News reference
This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.
Haemonetics shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $110 to $130.
BTIG Maintains Buy on Haemonetics, Raises Price Target to $130
HawkEye 360 Receives $36M Global Contracts During Q3
HawkEye 360, Inc. (NYSE:HAWK), the global leader in signals intelligence data and analytics, today announced $36 million in new international contracts during the third quarter ending September 30, 2026. The awards
Piper Sandler Initiates Coverage On Hawkeye 360 with Overweight Rating, Announces Price Target of $22
Piper Sandler analyst Clarke Jeffries initiates coverage on Hawkeye 360 (NYSE:HAWK) with a Overweight rating and announces Price Target of $22.